3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
37
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Neoplasms
9
Colorectal Neoplasms
9
Thyroid Carcinoma, Anaplastic
8
Neoplasm Metastasis
6
Multiple Myeloma
5
Glioma
5
Pancreatic Neoplasms
4
Brain Neoplasms
4
Thyroid Cancer, Papillary
3
Recurrence
3
Prostatic Neoplasms
3
Neurofibromatosis 1
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Ameloblastoma
3
Skin Neoplasms
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neurofibroma, Plexiform
2
Myelodysplastic Syndromes
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Colonic Neoplasms
2
Breast Neoplasms
2
Astrocytoma
2
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled